Intellia Therapeutics, Inc. (NTLA) stock
NTLANasdaqIn Vitro & In Vivo Diagnostic SubstancesFiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Nov 5, 2026Score 3/3025% above fair value
$9.70−0.85 (-8.06%)
Close on Nov 13, 2026Market cap $1.36BP/E –Yield –
Intellia Therapeutics total assets
Total assets on the balance sheet at the end of each period.
Intellia Therapeutics's total assets was $902.56M at Sep 30, 2026. For fiscal 2025 it was $842.13M, down 29.3% from the year before. Over ten years it grew 26.2% a year on average. The highest annual figure on record is $1.52B in fiscal 2022.
Annual total assets
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $842.13M | -29.3% |
| FY2024 | Dec 31, 2024 | $1.19B | -8.5% |
| FY2023 | Dec 31, 2023 | $1.30B | -14.4% |
| FY2022 | Dec 31, 2022 | $1.52B | +17.4% |
| FY2021 | Dec 31, 2021 | $1.29B | +91.4% |
| FY2020 | Dec 31, 2020 | $676.32M | +102.3% |
| FY2019 | Dec 31, 2019 | $334.28M | -3.8% |
| FY2018 | Dec 31, 2018 | $347.32M | -7.7% |
| FY2017 | Dec 31, 2017 | $376.24M | +25.8% |
| FY2016 | Dec 31, 2016 | $298.97M | +264.0% |
| FY2015 | Dec 31, 2015 | $82.14M | – |
Quarterly total assets
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q3 FY2026 | Sep 30, 2026 | $902.56M | -2.5% |
| Q2 FY2026 | Jun 30, 2026 | $857.16M | -4.6% |
| Q1 FY2026 | Mar 31, 2026 | $758.78M | -23.1% |
| Q4 FY2025 | Dec 31, 2025 | $842.13M | -29.3% |
| Q3 FY2025 | Sep 30, 2025 | $925.28M | -21.1% |
| Q2 FY2025 | Jun 30, 2025 | $898.89M | -24.6% |
| Q1 FY2025 | Mar 31, 2025 | $986.16M | -21.7% |
| Q4 FY2024 | Dec 31, 2024 | $1.19B | -8.5% |
| Q3 FY2024 | Sep 30, 2024 | $1.17B | -5.6% |
| Q2 FY2024 | Jun 30, 2024 | $1.19B | -10.0% |
| Q1 FY2024 | Mar 31, 2024 | $1.26B | -11.2% |
| Q4 FY2023 | Dec 31, 2023 | $1.30B | -14.4% |
| Q3 FY2023 | Sep 30, 2023 | $1.24B | +14.7% |
| Q2 FY2023 | Jun 30, 2023 | $1.32B | +19.2% |
| Q1 FY2023 | Mar 31, 2023 | $1.42B | +17.9% |
| Q4 FY2022 | Dec 31, 2022 | $1.52B | +17.4% |
| Q3 FY2022 | Sep 30, 2022 | $1.08B | -18.8% |
| Q2 FY2022 | Jun 30, 2022 | $1.11B | +65.2% |
| Q1 FY2022 | Mar 31, 2022 | $1.20B | +67.8% |
| Q4 FY2021 | Dec 31, 2021 | $1.29B | +91.4% |
| Q3 FY2021 | Sep 30, 2021 | $1.33B | +191.1% |
| Q2 FY2021 | Jun 30, 2021 | $672.24M | +37.0% |
| Q1 FY2021 | Mar 31, 2021 | $716.89M | +127.8% |
| Q4 FY2020 | Dec 31, 2020 | $676.32M | +102.3% |
| Q3 FY2020 | Sep 30, 2020 | $458.56M | +32.3% |
| Q2 FY2020 | Jun 30, 2020 | $490.83M | +39.3% |
| Q1 FY2020 | Mar 31, 2020 | $314.75M | -8.6% |
| Q4 FY2019 | Dec 31, 2019 | $334.28M | -3.8% |
| Q3 FY2019 | Sep 30, 2019 | $346.64M | +7.9% |
| Q2 FY2019 | Jun 30, 2019 | $352.44M | +3.7% |
| Q1 FY2019 | Mar 31, 2019 | $344.36M | -4.2% |
| Q4 FY2018 | Dec 31, 2018 | $347.32M | -7.7% |
| Q3 FY2018 | Sep 30, 2018 | $321.23M | +28.9% |
| Q2 FY2018 | Jun 30, 2018 | $339.78M | +28.2% |
| Q1 FY2018 | Mar 31, 2018 | $359.55M | +28.7% |
| Q4 FY2017 | Dec 31, 2017 | $376.24M | +25.8% |
| Q3 FY2017 | Sep 30, 2017 | $249.17M | – |
| Q2 FY2017 | Jun 30, 2017 | $264.98M | – |
| Q1 FY2017 | Mar 31, 2017 | $279.26M | – |
| Q4 FY2016 | Dec 31, 2016 | $298.97M | – |
See a number that looks wrong?